Abstract

The discovery of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade and its successful clinical translation has revolutionized the concept of cancer immunotherapy. Although immunecheckpoint-targeting antibody has shown impressive results in a diverse array of cancers, their cell-based manufacturing process influences production capacity and cause variation between batches. Aptamers are synthetic DNA or RNA oligonucleotides that encompass antibody-mimicking functions. With its chemically synthetic nature, aptamer can be produced in large scale with controllable batch variations and lower manufacturing cost. Here, we report the development of a CTLA-4 antagonizing DNA aptamer, termed aptCTLA-4, using the cell-based SELEX and next-generation sequencing. The aptCTLA-4 exhibits good binding affinity (dissociation constant, 11.8 nM). In vitro lymphocyte proliferation assays demonstrated that the aptCTLA-4 promotes T cell proliferation, and in vivo murine syngeneic tumor models further revealed its tumor-inhibitory effects. Our data suggest the translational potential of the aptCTLA-4 to be developed into a therapeutic aptamer.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.